Iván R. González/X
Feb 26, 2025, 16:33
Iván R. González: Neoadjuvant Nivolumab Plus Ipilimumab versus Chemotherapy in Patients with Resectable NSCLC
Iván R. González, Medical Oncologist at the Comprehensive Cancer Center, Hospital Ángeles Puebla, shared on X:
“Neoadjuvant Nivolumab Plus Ipilimumab Shows Trend Towards Long-Term Clinical Benefit versus Chemotherapy in Patients with Resectable NSCLC: Findings from the CheckMate 816 Study.
Objectives:
- Evaluate the efficacy and safety of neoadjuvant nivolumab plus ipilimumab compared to chemotherapy in patients with resectable non-small cell lung cancer (NSCLC).
Inclusion Criteria:
- Adults with stage IB-IIIA resectable NSCLC.
Key points:
- Median event-free survival (EFS) was 54.8 months for nivolumab plus ipilimumab vs. 20.9 months for chemotherapy.
- Three-year overall survival (OS) rates were 73% vs. 61%, respectively.
- Pathologic complete response (pCR) rates were 20.4% vs. 4.6%. Grade 3-4 treatment-related adverse events occurred in 14% vs. 36% of patients.
Neoadjuvant nivolumab plus ipilimumab demonstrated potential long-term clinical benefits over chemotherapy in resectable NSCLC, with a more favorable safety profile.”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Feb 26, 2025, 16:32
Feb 26, 2025, 16:31
Feb 26, 2025, 15:47
Feb 26, 2025, 15:38
Feb 26, 2025, 15:34
Feb 26, 2025, 15:33
Feb 26, 2025, 15:22
Feb 26, 2025, 15:16